Developing new economic models to incentivise antibiotic discovery and development activities while safeguarding the efficacy of antibiotics by researching and advocating their appropriate use.
DRIVE-AB Partners Help Lead on New International Public-Private Partnership CARB-X to Fund Antibiotic Preclinical R&D
DRIVE-AB welcomes today's announcement of the establishment of The Combating Antibiotic Resistant Bacteria Biopharmaceutical...
DRIVE-AB Metrics & Indicators of Responsible Antibiotic Use Included in ECDC’s Draft EU Guidelines of Human Antibiotic Use
The European Commission has asked the European Centre for Disease Prevention and Control (ECDC) to developEMA Recommends Countries Reduce Colistin Use in Animals
The European Medicines Agency (EMA) has recommended that colistin-containing medicines should only...Prof Otto Cars Interviewed About “Post-Antibiotic Era”
DRIVE-AB Work Package 2 partner Prof Otto Cars, Professor of Infectious Diseases at Uppsala University,...WHO Updates List of Antibiotics Most Critical to Human Medicine
A World Health Organization (WHO) expert panel has updated the list of antibiotics that are considered to be most...